HMR SELDANE FAMILY TO BE DISCONTINUED FEB. 1 FOLLOWING APPROVAL OF SELDANE D SUCCESSOR ALLEGRA D; HMR WILL NOT WITHDRAW TERFENADINE NDA
Executive Summary
FDA will continue its administrative process to withdraw the NDA for Seldane following Hoechst Marion Roussel's announcement that it will discontinue sales of the antihistamine line effective Feb. 1.